Skip to main content

Table 2 Multivariate analysis of BCSS in the whole and matched cohorts

From: Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?

Variable

Whole cohort

Matched cohort

HR (95% CI)

P

HR (95% CI)

P

Diagnosis year

 2000–2003

Ref.

 

Ref.

 

 2004–2008

0.76 (0.72–0.80)

< 0.001

0.69 (0.56–0.86)

0.001

 2009–2012

0.63 (0.57–0.69)

< 0.001

0.64 (0.45–0.92)

0.014

Race

 NHW

Ref.

 

Ref.

 

 NHB

1.51 (1.39–1.64)

< 0.001

1.27 (0.91–1.78)

0.157

 NHAIAN

1.42 (1.01–1.99)

0.047

4.73 (1.16–19.27)

0.030

 NHAPI

0.89 (0.79–0.99)

0.047

1.29 (0.83–2.00)

0.266

 Hispanic

1.11 (1.01–1.22)

0.036

0.94 (0.61–1.44)

0.760

 Unknown

0.45 (0.20–1.01)

0.050

0.00 (0.00–12.40)

0.925

Marital status

 Married

Ref.

 

Ref.

 

 Single

1.17 (1.08–1.27)

< 0.001

1.10 (0.78–1.57)

0.571

 Widowed

1.26 (1.17–1.36)

< 0.001

1.25 (1.01–1.55)

0.045

 Divorced

1.23 (1.13–1.33)

< 0.001

1.15 (0.82–1.62)

0.416

 Unknown

1.14 (0.98–1.32)

0.095

0.97 (0.54–1.74)

0.914

Age (years)

 18–49

Ref.

 

Ref.

 

 50–64

0.96 (0.89–1.03)

0.200

0.69 (0.48–0.99)

0.042

 65–79

1.69 (1.56–1.83)

< 0.001

1.13 (0.81–1.57)

0.466

 80–

3.08 (2.74–3.46)

< 0.001

1.72 (1.23–2.41)

0.001

T stage

 T1mic

Ref.

 

Ref.

 

 T1a

1.29 (0.76–1.68)

0.065

1.35 (0.76–2.40)

0.309

 T1b

1.78 (1.14–2.28)

< 0.001

1.94 (1.14–3.33)

0.015

 T1c

2.93 (2.15–3.73)

< 0.001

3.62 (2.15–6.10)

< 0.001

Histological type

 Ductal

Ref.

 

Ref.

 

 Lobular

0.94 (0.87–1.01)

0.077

0.87 (0.67–1.13)

0.295

 Favorable

0.61 (0.52–0.72)

< 0.001

0.99 (0.69–1.42)

0.966

 Others

0.69 (0.57–0.83)

< 0.001

0.93 (0.46–1.88)

0.840

Grade

 I

Ref.

 

Ref.

 

 II

1.75 (1.62–1.90)

< 0.001

1.62 (1.27–2.06)

< 0.001

 III

2.68 (2.45–2.93)

< 0.001

2.50 (1.89–3.32)

< 0.001

 Unknown

1.81 (1.58–2.09)

< 0.001

1.32 (0.88–2.00)

0.180

ER

 Negative

Ref.

 

Ref.

 

 Positive

0.73 (0.67–0.80)

< 0.001

0.67 (0.48–0.92)

0.013

 Unknown

0.69 (0.57–0.85)

< 0.001

0.38 (0.19–0.75)

0.006

PR

 Negative

Ref.

 

Ref.

 

 Positive

0.74 (0.69–0.79)

< 0.001

0.74 (0.57–0.97)

0.027

 Unknown

1.00 (0.83–1.20)

0.998

1.48 (0.80–2.72)

0.213

Chemotherapy

 No

Ref.

 

Ref.

 

 Yes

1.49 (1.39–1.58)

< 0.001

1.29 (0.94–1.77)

0.115

Surgical axillary staging

 No

Ref.

 

Ref.

 

 Yes

0.68 (0.60–0.76)

< 0.001

0.70 (0.59–0.83)

< 0.001

  1. BCSS breast cancer-specific survival, HR hazard ratios, CI confidence intervals, NHW non-Hispanic white, NHB non-Hispanic black, NHAIAN non-Hispanic American Indian/Alaska native, NHAPI non-Hispanic Asian or Pacific Islander, ER estrogen receptor, PR progesterone receptor
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us